NCT06739668Completed
Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction
Microtesla Magnetic Therapy (MMT) Treatment of Post-acute Sequelae of SARS CoV-2 (PASC): Controlled Pilot Study
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction. Total study duration will be 8 weeks, including 4 weeks of treatment and 4 weeks of untreated follow up.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 17 Dec 2024
- Start date
- 19 Dec 2024
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06739668
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 19 Dec 2024 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of cognitive dysfunction present prior to SARS CoV-2 infection
- Currently taking immunomodulatory medication on an ongoing basis (NSAIDs, corticosteroids, cytokine antagonists, IVIG)
- Change in anti-depressant or other psychoactive medication or dose in the last 90 days
- Serious immune/autoimmune diagnoses prior to SARS-CoV-2 infection
- ME/CFS diagnosis prior to first SARS-CoV-2 infection
Other illness
- History of bipolar disorder, psychotic disorder, substance use disorder
- Any serious unstable medical or neurologic condition
- History of severe head injury (as defined by loss of consciousness for ≥30 minutes) or stroke in the past 12 months
- Existing diagnosis of Post-treatment Lyme Disease Syndrome
Other
- Febrile (\> 99 F) at the time of the enrollment visit
- Enrollment in another interventional clinical trial in the last 90 days or during the study period
- Recent SARS CoV-2 reinfection in the last 30 days or during the study period
- Recent SARS CoV-2 vaccination in the last 30 days or plans to be vaccinated during the 8 week study period
- Cranially implanted devices or metal
- Pregnant or plan to become pregnant during the study as indicated by positive pregnancy test
- Inability to achieve appropriate positioning of the study device on the head
Who the study is looking for
- 18 years of age or older
- English Speaking
- SARS CoV-2 infection as documented by laboratory nucleic acid amplification test or antibody test ≥ 6 months from screening or signed attestation of positive test result
- Experiencing PASC symptoms ≥ 6 months
- Objective cognitive impairment on neuropsychological measures (as defined by a z-score ≥1 standard deviation below the normative mean) in executive functioning
- Individuals of childbearing age agreeing to use a highly effective form of birth control
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.